KRAS inhibitor daraxonrasib extends pancreatic cancer survival, while GLP-1 drugs linked to breast cancer benefits

Revolution Medicines' KRAS‑targeting drug daraxonrasib has shown a significant extension of life for patients with metastatic pancreatic cancer in a late‑stage clinical trial. The pill, taken three times daily, binds and disables the KRAS protein—long considered “undruggable”—and is also being evaluated for lung and colon cancers. The FDA has placed daraxonrasib under accelerated review and may grant approval later this year, though the drug can cause skin rash, diarrhea, fatigue and other side effects.

Separately, a study of nearly 8,000 women diagnosed with breast cancer between 2006 and 2023 found that users of GLP‑1 receptor agonists (such as Ozempic, Wegovy and Mounjaro) experienced lower overall mortality and a reduced risk of cancer recurrence over a ten‑year follow‑up. These drugs, originally approved for type‑2 diabetes and weight loss, may improve outcomes by addressing obesity‑related inflammation and metabolic dysfunction. Researchers caution that further trials are needed to confirm whether the benefits arise from weight control, cardiometabolic health, or direct anti‑cancer mechanisms.